Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - REVA Medical, Inc.c24249exv99w1.htm
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2011

REVA MEDICAL, INC.
(Exact name of registrant as specified in its charter)

         
Delaware   000-54192   33-0810505
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
5751 Copley Drive, San Diego, CA
  92111
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 966-3000

 
 
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1


 

Item 7.01 Regulation FD Disclosure.

On November 8, 2011, Dr. Alexandre Abizaid will make a presentation at the Transcatheter Cardiovascular Therapeutics Conference in San Francisco. The presentation materials to be delivered at the conference are attached hereto as Exhibit 99.1. A copy of the slides will be posted under the Investor Relations section of REVA’s website at www.revamedical.com.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Item 9.01   Financial Statements and Exhibits.

  (d)   Exhibits.
     
Exhibit No.   Description
 
   
99.1
  Transcatheter Cardiovascular Therapeutics Conference Presentation

 

2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.  

REVA Medical, Inc.

Date: November 7, 2011

/s/ Katrina Thompson                                          
Katrina Thompson
Chief Financial Officer
(principal financial and accounting officer)

 

3


 

Index to Exhibits  

     
Exhibit    
Number   Description of Exhibits
 
   
99.1
  Transcatheter Cardiovascular Therapeutics Conference Presentation

 

4